Study Title: Hippocampal Avoidance Whole-Brain Radiotherapy for Lung Cancer Brain Metastases
Summary
This study evaluated the effectiveness of a specific radiotherapy technique and cognitive testing in Chinese lung cancer patients with brain metastases. The results showed promising outcomes in terms of survival and cognitive function.
Key Findings
– The median survival for all patients was 14.8 months, with a progression-free survival of 6.7 months.
– Male sex and newly diagnosed stage IV disease were associated with poorer survival outcomes.
– The Hopkins Verbal Learning Test-Revised (HVLT-R) scores showed a decrease of approximately 9.8% at 6 months after radiotherapy compared to baseline.
– No severe side effects were observed in the patient group.
Conclusion
The study concluded that Hippocampal Avoidance Whole-Brain Radiotherapy with a Simultaneous Integrated Boost (HA-WBRT-SIB) is effective and preserves cognitive function in treating Chinese lung cancer brain metastases.
Clinical Trial Registration
This study was retrospectively registered on ClinicalTrials.gov with the ID NCT06289023.
Practical Solutions and Value
Our AI-driven platform, DocSym, consolidates clinical standards and research, making it easier for clinicians to access essential knowledge. Additionally, our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining operations and enhancing patient care. By utilizing AI, clinics can improve workflows and patient outcomes while reducing paper-based routines.
Learn more about our solutions at aidevmd.com.
